Dr. Richard Isaacson, United States
December 10, 2021
What does the Alzheimer's disease Cooperative Study–Activities of Daily Living endpoint tell us about cognitive change in Alzheimer’s clinical trials? Watch Dr. Richard Isaacson discuss advantages and limitations of the ADCS-ADL.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.